The diagnostic utility of flumazenil (a benzodiazepine antagonist) in coma of unknown etiology | Canada Hyperbarics Skip to main content
Clinical Trial Ann Emerg Med 1990

The diagnostic utility of flumazenil (a benzodiazepine antagonist) in coma of unknown etiology

Burkhart K, Kulig K — Ann Emerg Med, 1990

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers investigated how well flumazenil, a drug that blocks benzodiazepines, could help diagnose and treat two patients in a coma whose cause was unknown.

What They Found

Flumazenil awakened one patient who had ingested 20.5 mg of alprazolam, allowing doctors to reliably assess their injuries. In a second patient who ingested 7.5 mg of triazolam and attempted suicide with carbon monoxide, flumazenil completely resolved the coma, making hyperbaric oxygen treatment unnecessary.

Canadian Relevance

This study covers carbon monoxide poisoning, which is a Health Canada-recognised indication for hyperbaric oxygen therapy.

Study Limitations

The study involved only two patients, which is a very small sample size for drawing broad conclusions about the widespread utility of flumazenil.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Clinical Trial
Category Carbon Monoxide Poisoning
Source Pubmed
PubMed ID 2106810
Year Published 1990
Journal Ann Emerg Med
MeSH Terms Adult; Alprazolam; Carbon Monoxide Poisoning; Clinical Trials as Topic; Coma; Double-Blind Method; Drug Overdose; Flumazenil; Humans; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Suicide, Attempted; Triazolam

Cite This Study

Share

This study relates to Carbon Monoxide Poisoning. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Carbon Monoxide Poisoning

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 17, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology